AURA BIOSCIENCES INC
AURANASDAQTrading Snapshot
- Day Range
- $6.22 – $6.41
- 52-Week Range
- $4.73 – $9.54
- Volume (shares)
- 541,814
- Avg Volume (shares)
- —
- Shares Outstanding
- 103.7M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -3.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.38
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +21.5%
AURA BIOSCIENCES INC
AURA
StockOtter · stockotter.spaceAbout AURA BIOSCIENCES INC
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.
Frazier Life Sciences Management L.P. grew its position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) by 39.2% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The f
Aura Biosciences to Participate in Upcoming Investor Conference
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, to
BlackRock Inc. Makes New Investment in Aura Biosciences, Inc. $AURA
BlackRock Inc. bought a new stake in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fi
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patien
ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURA
ADAR1 Capital Management LLC bought a new position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission